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Abstract 
A rare sign of some malignant tumors is a sudden eruption of multiple seborrheic keratoses called Leser-Trélat sign. 
Overproduction of insulin-like growth factor-2 (IGF2) or its precursor is the main mechanism related to non-islet cell 
tumor hypoglycemia. Doege-Potter syndrome is the name given to paraneoplastic hypoinsulinemic hypoglycemia 
in presence of a solitary fibrous tumor. This report describes a case of a patient with hypoinsulinemic hypoglycemia 
and Leser-Trélat sign associated with a malignant solitary fibrous tumor with IGF2 secretion. Both conditions have 
improved after tumor excision.
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Background
Cutaneous morphology can be modified by endocrine 
and metabolic diseases and skin lesions might serve as a 
window to the early diagnosis and treatment of various 
hormone-secreting tumors [1]. An example is a sudden 
eruption of multiple seborrheic keratosis called as Leser-
Trélat sign and it is more associated with adenocarcino-
mas although it may be related to other tumors indicating 
worse prognosis [2].
Different tumors can cause hypoglycemia. Among 
tumoral etiologies the insulinoma is the most common 
cause [3]. Nevertheless, other tumors unrelated to β cell 
may cause hypoinsulinemic hypoglycemia by producing 
insulin growth factor-2 (IGF2) or its precursor named 
as big-IGF2 [3–7]. Doege-Potter syndrome is a paraneo-
plastic hypoglycemia caused by solitary fibrous tumor [8, 
9]. This rare neoplasm can secrete an IGF2 precursor that 
is a pro-IGF2 or a big-IGF2 [9, 10].
This case report describes a non-diabetic 81-year-
old man who presented with Leser-Trélat sign and 
hypoglycemia secondary to a retroperitoneal malignant 
solitary fibrous tumor.
Clinical case
An 81-year-old man with primary hypothyroidism com-
plained about symptoms suggestive of hypoglycemia 
for 6  months, with progressive worsening, and abdomi-
nal pain. He reported rapidly progressive appearance of 
brownish warty lesions throughout his body, one of them 
already biopsied (seborrheic keratoses).
He showed, as important, in his physical examina-
tion, acromegaloid face, brown warty lesions on the face, 
trunk and upper limbs (Fig.  1a) and a palpable mass in 
the right flank. Hematologic, renal and liver function, 
electrolytes evaluation of his blood and sera were within 
normal range. The work-up to his hypoglycemia etiology 
is shown in the Table 1.
His abdominal magnetic nuclear resonance imaging 
showed a retroperitoneal expansive mass with 18.6  cm 
in diameter extremely closed to great abdominal ves-
sels (Fig. 2). Distant metastatic lesions were excluded by 
tomography screening.
To test the tumor production of IGF2 were col-
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(radioimmunoassay), confirming the hypothesis 
(Table 1).
During the 2 months wait period before surgery it was 
prescribed fractionated diet, oral prednisone (30 mg/day) 
plus overnight intravenous glucose solution infusion with 
sporadic episodes of mild hypoglycemia. By the surgery 
time an encapsulated tumor was resected (Fig.  2). His-
topathological and immunohistochemical analysis con-
firmed malignant solitary fibrous tumor.
The patient showed good health recovery and he was 
sent to home and to out-patient clinic follow-up without 
hypoglycemic crises and on oral prednisone treatment 
that was stopped 6 months later.
By out-patient clinic appointment he referred no 
hypoglycemic episodes and his acromegaloid features 
and cutaneous lesions shown an involution (Fig.  1b). 
He started on local radiotherapy but new tomogra-
phy screening showed pulmonary nodules suggestive of 
Fig. 1 Sign of Leser-Trélat. Multiple lesions on the face (a) and back of the patient (b) compatible with seborrheic keratoses
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metastatic disease though he did not present any further 
hypoglycemia. The patient decided for palliative care and 
died after 18 months from the diagnosis.
Discussion
Non-islet cell tumor hypoglycemia should be suspected 
in any patient with Whipple’s triad and hypoinsulinemic 
hypoglycemia [4], since several diseases, hormone defi-
ciencies and alcohol intake have been excluded [1, 11]. 
This patient had a palpable tumor and progressive skin 
lesions favoring tumoral etiology [3, 4, 7, 12].
The presence of seborrheic keratosis contributed to 
the suspected of neoplastic syndrome in this patient. 
This rare situation, [13] due to a tumor, is known as the 
Leser-Trélat sign. The first description comes from 1956 
by Hollander [2, 14]. Seborrheic keratosis usually appears 
as black or brown warty papules, sharply delineated, with 
3 mm mainly on the chest and back. It is a sign of senil-
ity but the eruptive and abruptly form can result from 
inflammatory skin diseases, adverse drug reaction or 
paraneoplastic syndrome [14, 15]. Lesions appear mainly 
on the chest and back, bigger than the usual and the pre-
existing lesions can increase in size [12].
It is more frequent (68 %) that the skin condition pre-
cedes the diagnosis of the tumor, [12, 13, 16] and it is 
resulted of the release of tumor growth factors [12]. The 
most frequent tumors involved are adenocarcinomas, but 
other tumors have been described [2, 16]. The best treat-
ment is the tumor resection, but the skin response is vari-
able [13]. Although the exactly pathogenesis is uncertain 
it involves the cytokines produced by the neoplastic cells 
as IGF1 and epidermal growth factor that act in the sur-
face of epidermal cells [16].
In half of the patients with non-islet cell tumor hypo-
glycemia, hypoglycemia comes after the tumor has been 
found [5] and fasting hypoglycemia and neuroglycopenic 
symptoms are more common. This tumor is most com-
monly diagnosed in the fifth or sixth decades of life and 
symptoms can be present for weeks or months before it 
[1, 3, 4, 6, 7, 12]. Weight loss, palpable mass and pain are 
the main clinical manifestations. In rare patients there is 
acromegaloid features [3, 7]. It was first described in 1929 
but only in 1988 it was associated with IGF2 production 
[3, 7, 17, 18].
Usually, 80 % of the circulating mature IGF2 stays inac-
tive bounded to insulin like growth factor binding pro-
tein 3 (IGFBP3) and to acid labile subunit [7, 19–21]. 
In patients with non-islet cell tumor the pool of big-
IGF2 increases and 80  % of this molecule is bounded 
to IGFBP3 only, forming a lower molecular weight that 
crosses the endothelial barrier and acts on insulin recep-
tors [4, 7, 20, 22].
Increased glucose uptake, lower insulin and glucagon 
secretion, decreased lipolysis and liver gluconeogenesis 
are some effects of the massive secretion of IGF2 that 
lead to hypoglycemia [3, 5]. Autocrine and paracrine 
action also promotes tumor growth. The big-IGF2 sup-
presses GH secretion and it causes synthesis reduction of 
IGF1, IGFBP2 [1, 3, 18, 20] increasing the bioavailability 
of IGF2 [1, 3, 4, 6, 20, 22].
Laboratorial tests can show normal level of IGF2 but 
elevated ratio of IGF2/IGF1. A ratio up to three is con-
sidered normal; if it is higher than ten, in the presence 
of non-ketotic hypoglycemia and suppressed GH, it is 
reported to be virtually pathognomonic of non-islet cell 
tumor hypoglycemia [7, 9, 11]. Measurement of free IGF2 
or its precursors are not widely available but it is known 
that free IGF2 and the ratio pro-IGF2/IGF1 are increased 
[1, 3, 4, 9]. The presence of lower levels of GH and IGF1 
and a positive response to glucagon-stimulation test can 
support the diagnosis when the IGF2 assays are unavail-
able [4].
The tumors are usually large and well differentiated, 
with epithelial or mesenchymal origin, slow grow-
ing, arising in thorax, pelvis, or retroperitoneum [1, 3, 
6]. The most common epithelial tumor is hepatocellu-
lar carcinoma and the mesenchymal are fibrosarcomas 
and solitary fibrous tumor [3, 5, 7, 10, 23]. The latter is 
a rare neoplasm, with a widespread distribution, involv-
ing pleura, lungs, pelvic and abdominal organs or ret-
roperitoneum [9, 10, 23]. It affects men and women 
equally, 50 % of then were asymptomatic and the major-
ity were found as incidentalomas on diagnosis. The most 
symptomatic tumors have extrathoracic location and 
Table 1 Laboratory tests confirming non-ketotic hypoin-
sulinemic hypoglycemia by IGF2 production
Test Result Cut-off
Morning cortisol (nmol/L) 259.34 171.05–535.24
Potassium (mmol/L) 4.2 3.5–5.0
Glucose (mmol/l) 2.22 3.88–5.49
Thyrotropin (mU/L) 3.07 0.27–4.2
Free T4 thyroxine (nmol/L) 0.013 0.011–0.021
Insulin (pmol/L) in hypoglycemia (2.22 mmol/L) <1.2 <18
Pro-insulin (pmol/L) in hypoglycemia 
(2.22 mmol/L)
1.56 <9.4
C Peptide (nmol/L) in hypoglycemia 
(2.22 mmol/L)
0.032 <0.198
β-hidroxybutyrate (µmol/L) <9.98 <429.91
Cortisol (nmol/L) in hypoglycemia (1.6 mmol/L) 427.64 >496.62
GH (μg/L) 0.09 ≤2.47
IGF-1 (μg/L) 32 55–166
IGF-2 (μg/L) 594 288–736
IGF-2/IGF-1 ratio 18.56 Up to 3
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mass effects (urinary retention, venous thrombosis and 
abdominal pain) [23].
Solitary fibrous tumor usually follow a benign clinical 
course although progress with distant metastasis or local 
recurrence may arise in some cases of large tumors. Extra 
thoracic location, paraneoplastic hypoglycemia, positive 
margins, high cellularity and mitotic activity, necrosis 
and nuclear pleomorphism are predictors of worse clini-
cal outcome [10, 23].
Hypoglycemia due to a solitary fibrous tumor was 
first reported by Doege and Potter in 1929. Since then, 
this finding is called Doege-Potter Syndrome but is very 
rare (less than 5 % of all solitary fibrous tumors) [8–10]. 
Among 79 cases of solitary fibrous tumors reported by 
Jason et al. only two presented hypoglycemia [23].
Regardless of histology, surgical resection is the 
therapy of choice. Complete surgical resection solves 
hypoglycemia [3, 7, 9, 24] and reverses those cases of 
acromegaloid fenotype [4]. When total resection is 
impossible the debulking technic can be used to ame-
liorate hypoglycemia or totally solve it in some cases 
[7]. Adjuvant therapy like tumor embolization, radio-
therapy or chemotherapy may bring success in other 
cases [3, 7].
Short- term measures for avoiding hypoglycemia 
include corticoid, glucagon, diazoxide and glucose intake. 
When hypoglycemia persists after surgical interven-
tion, multiple medical modalities have been employed. 
Although many of these tumors have somatostatin recep-
tors, the use of analogs was not effective in controlling 
Fig. 2 Solitary fibrous tumor from this patient. a MRI appearance of the mass in the coronal plane shows 18.6 cm in maximal diameter. b MRI 
T2-weighted image in the sagittal plane demonstrates the retroperitoneal location of the tumor. c contrast-enhanced MRI transverse plane indicates 
a lobulated tumor with solid and cystic componentes. d Photograph of the dissected specimen weighing 1.5 kg presents two nodular masses 
measuring 14.3 and 13 cm with irregular shape and connected by a fibroadipose tissue. There were extensive areas of necrosis
Page 5 of 5Mathez et al. Diabetol Metab Syndr  (2016) 8:33 
hypoglycemia and somatostatin analogue scintigraphy 
could not predict treatment response [3].
There are many reports of successful treatment with 
recombinant growth hormone, although it does not nor-
malize IGF2 levels. Nevertheless, this therapy is expen-
sive, requires high doses, and has many adverse effects [4, 
12]. It’s use should be avoided when there are acromega-
loid features [4].
The best clinical treatment option is the use of gluco-
corticoids with immediate effect on hypoglycemia in 
doses equivalent to 30–60  mg/day of prednisone [3, 4]. 
Moderate to high doses also could promote tumor reduc-
tion [7]. It is the only medical treatment that can sup-
press tumor production of IGF2, leading to normal levels 
of C-peptide, insulin and glucose [7, 14].
According to the English literature review, Leser-Trélat 
sign and hypoinsulinemic hypoglycemia by a solitary 
fibrous tumor is extremely rare. Whipple’s triad and 
hypoinsulinemic hypoglycemia, with low levels of GH 
and IGF1 suggest the diagnosis and the increase of IGF2/
IGF1 rate confirms. Some weeks after the surgery the 
patient showed remission of hypoglycemia without glu-
cocorticoids use and improvement of seborrheic kerato-
sis and acromegaloid features.
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